Literature DB >> 26424518

The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF.

Kevin C Wilson1, Ganesh Raghu2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26424518     DOI： 10.1183/13993003.01335-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  8 in total

1.  Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients.

Authors:  Alessandro Giuseppe Fois; Anna Maria Posadino; Roberta Giordo; Annalisa Cossu; Abdelali Agouni; Nasser Moustafa Rizk; Pietro Pirina; Ciriaco Carru; Angelo Zinellu; Gianfranco Pintus
Journal:  Oxid Med Cell Longev       Date:  2018-10-21       Impact factor: 6.543

Review 2.  Recipient selection process and listing for lung transplantation.

Authors:  Geert M Verleden; Lieven Dupont; Jonas Yserbyt; Veronique Schaevers; Dirk Van Raemdonck; Arne Neyrinck; Robin Vos
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 3.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

4.  Interstitial inflammation and pulmonary fibrosis in COVID-19: The potential role of cytostatic therapy for severe lung injury.

Authors:  Elena V Filimonova; Lyubov A Davydova; Mariana A Lysenko; Sergey V Tsarenko
Journal:  Respir Med Case Rep       Date:  2022-05-27

Review 5.  The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease.

Authors:  Anna-Maria Hoffmann-Vold; Yannick Allanore; Elisabeth Bendstrup; Cosimo Bruni; Oliver Distler; Toby M Maher; Marlies Wijsenbeek; Michael Kreuter
Journal:  Respir Res       Date:  2020-07-23

6.  Discovery of a new class of integrin antibodies for fibrosis.

Authors:  Ji Zhang; Tao Wang; Ashmita Saigal; Josephine Johnson; Jennifer Morrisson; Sahba Tabrizifard; Scott A Hollingsworth; Michael J Eddins; Wenxian Mao; Kim O'Neill; Margarita Garcia-Calvo; Ester Carballo-Jane; DingGang Liu; Taewon Ham; Qiong Zhou; Weifeng Dong; Hsien-Wei Meng; Jacqueline Hicks; Tian-Quan Cai; Taro Akiyama; Shirly Pinto; Alan C Cheng; Thomas Greshock; John C Marquis; Zhao Ren; Saswata Talukdar; Hussam Hisham Shaheen; Masahisa Handa
Journal:  Sci Rep       Date:  2021-01-22       Impact factor: 4.379

7.  Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody.

Authors:  Dong Weng; Zhao-Fang Yin; Shan-Shan Chen; Xian He; Nan Li; Tao Chen; Hui Qiu; Meng-Meng Zhao; Qin Wu; Nian-Yu Zhou; Li-Qin Lu; Dan-Li Tang; Jia-Cui Song; Hui-Ping Li
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

8.  Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis.

Authors:  J Guiot; B Bondue; M Henket; J L Corhay; R Louis
Journal:  BMC Pulm Med       Date:  2016-05-23       Impact factor: 3.317
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.